Novartis-Arrowhead, Servier-Ideaya partnerships refresh balance sheets: Deals Report

Arrowhead and Ideaya each received nine-figure upfront sums in deals with pharmas this week, while venture-backed Enlaza entered a discovery deal with Vertex that will supplement the biotech’s $100 million series A from 2024.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said Tuesday that Novartis AG (SIX:NOVN; NYSE:NVS) is paying $200 million up front for rights to ARO-SNCA, its preclinical RNAi therapy targeting α-synuclein (SNCA) to treat synucleinopathies including Parkinson’s disease. The deal also covers use of Arrowhead's Targeted RNAi Molecule (TRiM) platform for other undisclosed targets...